Targeting Programmed Cell Death 1 in Ovarian Cancer

Affiliations

¹ Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; and Swiss Institute of Bioinformatics, Lausanne, Switzerland.
² Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and Ludwig Institute Branch at the University of Lausanne, Lausanne, Switzerland george.coukos@chuv.ch.

Editorial

Krisztian Homicsko et al. J Clin Oncol. 2015.

. 2015 Dec 1;33(34):3987-9.

doi: 10.1200/JCO.2015.63.7785. Epub 2015 Oct 26.

¹ Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; and Swiss Institute of Bioinformatics, Lausanne, Switzerland.
² Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and Ludwig Institute Branch at the University of Lausanne, Lausanne, Switzerland george.coukos@chuv.ch.

No abstract available

Comment on

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I. Hamanishi J, et al. J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8. J Clin Oncol. 2015. PMID: 26351349 Clinical Trial.